Verônica Torres Costa e Silva

Dr. Verônica Torres Costa e Silva


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in Kidney International
Verified
Journal Article
Closed access
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
LGLuiz A. Gil
Luiz A. Gil
LILesley A. Inker
Lesley A. Inker
RCRenato A. Caires
Renato A. Caires
ECElerson Costalonga
Elerson Costalonga
EBEmmanuel A. Burdmann
Emmanuel A. Burdmann

23 March 2023 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
LGLuiz A. Gil
Luiz A. Gil
LILesley A. Inker
Lesley A. Inker
RCRenato A. Caires
Renato A. Caires
ECElerson Costalonga
Elerson Costalonga
EBEmmanuel A. Burdmann
Emmanuel A. Burdmann

26 March 2024 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
LGLuiz A. Gil
Luiz A. Gil
LILesley A. Inker
Lesley A. Inker
RCRenato A. Caires
Renato A. Caires
ECElerson Costalonga
Elerson Costalonga
EBEmmanuel A. Burdmann
Emmanuel A. Burdmann

16 April 2024 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
OAOgechi M. Adingwupu
Ogechi M. Adingwupu
LILesley A. Inker
Lesley A. Inker

20 April 2022 in Kidney International
Verified
Journal Article
Closed access
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
LILesley A. Inker
Lesley A. Inker
EBEmmanuel A. Burdmann
Emmanuel A. Burdmann
ALAndrew S. Levey
Andrew S. Levey

28 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RCRenato A. Caires
Renato A. Caires
ECElerson C. Costalonga
Elerson C. Costalonga
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
Carboplatin, a second-generation platinum-based therapy, is widely indicated for first-line treatment of selected solid tumors. Furthermore, it represents a well-established alternative to cisplatin in populations characterized by chronic kidney disease (CKD) or clinical frailty. The renal profile of carboplatin toxicity is most commonly linked to hypomagnesemia, and less frequently to acute kidney injury (AKI) or a persistent decline in GFR. While hypomagnesemia is the most frequent renal adverse effect, severe episodes that impact anticancer treatment are uncommon. Reductions in GFR carry significant clinical implications because they directly affect carboplatin dosing and drive cumulative hematologic toxicity that leads to adverse clinical events, which may be more relevant in older and sarcopenic patients. Carboplatin toxicity is highly dependent on systemic exposure and is quantified by the area under the concentration–time curve (AUC). Inaccurate estimation of GFR, particularly when using the Cockcroft–Gault (CG) equation, frequently leads to GFR overestimation and carboplatin overdose. Thus, precise dose adjustment according to GFR is of the utmost importance. In this review, we examine the renal complications associated with carboplatin, including the reported incidence and clinical patterns of kidney injury, with particular emphasis on dose-adjustment strategies based on GFR, encompassing patients with CKD and those receiving dialysis, as well as practical considerations for the prevention and management of carboplatin nephrotoxicity.